Study of 18F-Fluoro-PEG6-IPQA

Inclusion Criteria:

1. All patients must give written informed consent
2. Patients should have pathologically or cytologically confirmed non-small cell lung cancer with clinical or radiological evidence that it is not amenable to therapy with curative intent
3. Patients should be potential candidates for therapy with an EGFR tyrosine kinase inhibitor or with an anti-EGFR monoclonal antibody by clinical criteria.
4. Patients should have clinical characteristics that would suggest an increased probability of benefit from an EGFR inhibitor. Specifically, they should have either: "Less than a 10 pack-year smoking history AND a latency period from last tobacco use to diagnosis of longer than 10 years AND either lung adenocarcinoma or NSCLC not otherwise specified, OR "Known EGFR mutations OR high EGFR gene copy number"
5. Patients should have at least one tumor deposit that is > 1.0 cm in diameter, and that is amenable to imaging
6. Patients should be ECOG performance status 0-2
7. Patients with brain metastases are eligible provided they meet all other eligibility criteria and do not require corticosteroids or enzyme-inducing anticonvulsants and provided it is felt clinically that they will not require radiotherapy in the three (3) weeks subsequent to their participation in the study
8. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Childbearing potential will be defined as women who have had menses within the past 12 months, who have not had tubal ligation or bilateral oophorectomy. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately. The patient, if a man, agrees to use effective contraception or abstinence
9. The patient must be considered legally capable of providing his or her own consent for participation in this study
10. Subjects must be at least 18 years of age

Exclusion Criteria:

1. Prior therapy with an EGFR inhibitor or an anti-EGFR monoclonal antibody
2. Radiotherapy, chemotherapy or any investigational agent within the previous 4 weeks of administrating 18F-PEG6-IPQA for PET/CT imaging.
3. A non-investigational targeted agent within the previous 2 weeks of 18F-PEG6-IPQA for PET/CT imaging.
4. Thoracic or abdominal surgery within the previous 2 weeks of 18F-PEG6-IPQA for PET/CT imaging.
5. A tumor that is known to have a K-ras mutation
6. Squamous cell, large cell undifferentiated, neuroendocrine or small cell undifferentiated carcinoma of the lung
7. A known other currently active malignancy. (Benign tumors and benign polyps, basal cell carcinomas of skin, superficial papillary bladder tumors, and pre-invasive carcinoma of the cervix are permitted)
8. Physical inability to undergo a scanning procedure (e.g., inability to lie flat for the required period of time - three sessions of roughly an hour each with ten minutes' rest in between)
9. Serum creatinine >1.5 x ULN, bilirubin >1.5 x ULN, AST > 3 x ULN
10. 10. Hemoglobin < 8 g/dL, absolute neutrophil count < 1,500/mm3, platelet count <100,000/mm3
11. Potentially life-threatening arrhythmia; myocardial infarct within the previous 3 months; unstable angina, or angina at rest; congestive heart failure (New York Heart Association Functional Classification class II or worse), uncontrolled hypertension (systolic BP > 160 or diastolic BP >100).
12. Active acute infection (i.e. currently treated with antibiotics). Patients with chronic infections such as hepatitis B or C, mycobacterium avium or similar infections will be eligible provided they meet all other eligibility criteria.
13. Oxygen saturation <90% on room air
14. Clinical requirement for systemic corticosteroids for control of cerebral edema or for enzyme-inducing anticonvulsants. (Inhaled steroids and systemic steroids for COPD are permitted).
15. Pregnant or nursing
16. Any condition that is unstable or could jeopardize the safety of the patient and his or her compliance in the study, in the investigator's judgment